FDA unveils long-awaited guidance on new pathway for individualized therapiesnews2026-02-23T16:30:45+00:00February 23rd, 2026|Endpoints News|
Flagship’s Generate targets $2B+ valuation with Nasdaq IPOnews2026-02-23T16:27:28+00:00February 23rd, 2026|Endpoints News|
AbbVie budgets $380M for obesity and neuroscience API facilities in Chicagonews2026-02-23T16:00:44+00:00February 23rd, 2026|Endpoints News|
Frontier, Harbour do licensing deals with GSK, Solsticenews2026-02-23T15:03:25+00:00February 23rd, 2026|Endpoints News|
A federal experiment opens up a new market for digital health — if it worksnews2026-02-23T15:00:15+00:00February 23rd, 2026|Endpoints News|
Roche to stop work on bone health treatment for Duchennenews2026-02-23T14:40:19+00:00February 23rd, 2026|Endpoints News|
Merck reorganizes; Blackstone to fund trials for J&J drugnews2026-02-23T14:25:25+00:00February 23rd, 2026|Endpoints News|
First test of gene therapy for rare form of autism is underwaynews2026-02-23T14:00:16+00:00February 23rd, 2026|Endpoints News|
Gossamer Bio’s potential Winrevair competitor fails pivotal trialnews2026-02-23T13:00:43+00:00February 23rd, 2026|Endpoints News|
Gilead to buy cell therapy partner Arcellx in deal valued at $7.8Bnews2026-02-23T11:06:14+00:00February 23rd, 2026|Endpoints News|
